New Chief of Staff, Medical Director and VP of Product join executive team to unite clinical expertise, AI innovation, and proven product scaling to transform prostate cancer diagnostics and treatment planning
SAN FRANCISCO, Oct. 8, 2025 /PRNewswire/ -- Nucs AI, a leader in AI-powered radiology solutions for prostate cancer, today announced the expansion of its leadership team with the appointments of Andrew Findley as Chief of Staff, Dr. Jayashri Pawar as Medical Director, and Will Plogger as Vice President of Product. They join co-founders CEO Nijat Ahmadov and CTO Farid Yagubbayli, forming a uniquely qualified leadership team that blends deep clinical expertise, AI innovation, and proven product and business-building experience to advance the company's mission of transforming prostate cancer diagnostics with AI-driven insights and accelerating precision medicine for cancer care.
Nucs AI's platform is designed to address one of oncology's most urgent challenges–ensuring patients receive effective, targeted therapy at the right time. With radiologists under strain and more than half of advanced prostate cancer patients not benefiting from popular radioligand therapies, there is a pressing need for tools that provide clarity, standardization, and actionable insight.
New Leadership Appointments
Andrew Findley, Chief of Staff
Findley brings strategic and operational expertise shaped across healthcare technology and consulting. At Lyra Health, he led go-to-market strategy and operations, building forecasting models, market entry plans, and systems that helped scale access to mental health care for some of the world's largest employers. Earlier in his career at ZS Associates and Deloitte, he advised pharmaceutical, biotech, and medtech companies on commercialization, product launches, and global market expansion. Having grown up with a father who was a Navy surgical oncologist and supported both his aunt and mother through breast cancer, Findley brings a personal connection that fuels his dedication to Nucs AI's mission of improving cancer care.
Dr. Jayashri Pawar, Medical Director
A practicing radiologist with expertise across oncology, neuroradiology, musculoskeletal, and women's imaging, Dr. Pawar brings the clinical rigor and perspective needed to ensure Nucs AI's products meet the realities of patient care. She has served as an independent reader for oncology trials, led a mammography unit focused on early breast cancer detection, and published research in leading journals including RSNA and MICCAI. In her role, Dr. Pawar will guide clinical validation, product refinement, and ensure that Nucs AI's AI models integrate seamlessly into workflows and deliver meaningful impact.
Will Plogger, Vice President of Product
Plogger joins from Imagen Technologies, where he was among the company's first employees and helped grow it to over 200 people and $20 million in annual revenue. He led teams to achieve FDA clearance for multiple AI imaging products, built product and clinical operations teams from scratch, and scaled 24/7 diagnostic services across more than a dozen states. Inspired by his mother's breast cancer journey, Plogger brings both personal motivation and proven expertise in scaling AI medical imaging products nationwide.
In addition to strengthening its executive team, Nucs AI is building a world-class Medical Advisory Board composed of leading clinicians and researchers in oncology and radiology. This group will provide critical perspective on product development and clinical validation, ensuring that Nucs AI's solutions are aligned with real-world practice while advancing the standard of care.
"Nucs AI is tackling one of the most complex challenges in oncology—bringing consistency, speed, and predictive insight to prostate cancer imaging," said CEO Nijat Ahmadov. "With Andrew's operational expertise, Jayashri's clinical insight and Will's track record in scaling FDA-cleared imaging products, we are building a leadership team that connects every part of the chain from AI research and model development, to clinical integration, to large-scale adoption. This expansion underscores our ambition to be a top leader in medical AI"
"This team has a rare combination of skills," added CTO Farid Yagubbayli. "We have lived the problems of radiology, built the technology to solve them, and now have the clinical, product, and operational leadership in place to ensure those solutions are validated and scalable. Together, we're closing the gap between innovation and impact in prostate cancer care and beyond."
Nucs AI is building momentum with a pipeline of AI solutions and partnerships that span research institutions, hospitals, and clinical trial sponsors. The company is moving steadily toward regulatory clearance, wider adoption in care settings, and commercial scale.
About Nucs AI
Nucs AI is transforming precision oncology through AI-powered imaging and predictive analytics. Its suite of solutions—including DeepPSMA, SelectPSMA, and TrackPSMA—automates the detection, staging, and treatment response evaluation of prostate cancer, empowering clinicians to make faster, more informed decisions. With global partnerships including Johns Hopkins and other leading institutions, Nucs AI is advancing the future of molecular imaging and setting new standards for AI-assisted diagnostics.
For more information, visit www.nucs.ai.
SOURCE Nucs AI

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

Newsrooms &
Influencers

Digital Media
Outlets

Journalists
Opted In
Share this article